Progyny Cash Flow Statement
NASDAQ: PGNYHealth CareMisc Health and Biotechnology ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Progyny free cash flow
In fiscal 2025, Progyny generated $210.2 million of operating cash flow and spent $18.4 million on capital expenditures. That left free cash flow of $191.8 million, a free-cash-flow margin of 14.9% of revenue. Free cash flow was up 10.4% from the prior year's $173.7 million.
Progyny returned $81.7 million to shareholders through share repurchases, equal to 43% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Progyny cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | 58.52M | 54.34M | 62.04M | 30.36M | 65.77M | 46.46M | -8.57M | 661.00K | -12.45M |
| Net Income growth (YoY) | +7.70% | -12.41% | +104.35% | -53.84% | +41.56% | — | -1396.37% | — | — |
| Depreciation & Amortization | 4.95M | 3.17M | 2.28M | 1.60M | 1.30M | 1.91M | 2.13M | 1.88M | 1.56M |
| Stock-Based Compensation | 131.87M | 128.13M | 122.61M | 100.75M | 33.71M | 12.82M | 5.06M | 3.00M | 1.56M |
| Change in Working Capital | 11.69M | -22.12M | -28.43M | -71.56M | -50.16M | -10.65M | -25.96M | -2.51M | -3.15M |
| Operating Cash Flow | 210.19M | 179.10M | 188.81M | 80.39M | 26.04M | 36.20M | -1.53M | 2.27M | -9.47M |
| Capital Expenditures | -18.41M | -5.41M | -3.64M | -3.24M | -2.13M | -1.04M | -2.96M | -579.00K | -612.00K |
| Investing Cash Flow | -159.01M | 195.79M | -200.53M | -43.87M | 8.77M | -40.03M | -2.76M | 1.90M | -612.00K |
| Share Repurchases | -81.66M | -300.28M | 0 | 0 | — | — | -185.00K | -1.21M | — |
| Financing Cash Flow | -99.36M | -309.88M | -11.07M | -7.86M | -13.70M | -6.25M | 84.55M | -8.74M | 11.77M |
| Net Change in Cash | -48.12M | 65.02M | -22.78M | 28.66M | 21.11M | -10.08M | 80.25M | -4.56M | 1.68M |
| Free Cash Flow | 191.78M | 173.70M | 185.17M | 77.15M | 23.91M | 35.17M | -4.49M | 1.69M | -10.09M |
This table shows 9 annual periods of Progyny's cash flow statement, from FY 2025 back to FY 2017, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PGNY's reporting calendar. What is a cash flow statement?